Warning: Use of undefined constant user_level - assumed 'user_level' (this will throw an Error in a future version of PHP) in /home/f2b2rt5q2xqh/public_html/wp-content/plugins/ultimate-google-analytics/ultimate_ga.php on line 524
The Beijing Clinical Cancer Research Center
Established in 1999, The Beijing Clinical Cancer Gene Research Center (BCCGRC) is a private research institution focused on biological genetic therapies for cancer. BCCGRC is at the global forefront in our development of anti-cancer therapeutic drugs that are collectively termed BRM, or biological response modifiers.
Our mission is to improve the quality of life for our patients through our drug therapeutic programs, and we strive to make positive contributions to society by developing anti-cancer treatment that is both effective and safe for our patients.
Ze-Guang Wang, MD, Founder and President
Dr. Ze-Guang Wang is the head of research in the discovery and development of BRM therapeutic drugs. He is a Western-trained gastrointestinal oncologist who received his medical degree from the Beijing Medical University, class of 1980.
Dr. Wang began his research in clinical oncology in 1987, and in 1989, Dr. Wang went overseas to do his graduate research in biochemistry and AIDS at the University of Southern California, receiving his Master’s degree in 1992. While doing his graduate research on AIDS, he discovered that biological response modifiers (BRM) were effective in the treatment of malignant tumors. Dr. Wang continued his research upon his return to Beijing, China and by 1999, he and his team of researchers were approved by the government to establish The Beijing Clinical Cancer Gene Research Center.
In 2006, he was approved and licensed by the China State Food and Drug Administration to commercially market BRM therapeutic drugs in the domestic market. From the founding of BCCGRC to today, Dr. Wang and his team of physicians have treated more than 42,000 patients with BRM therapeutic drugs.
Dr. Wang is a member of the American Society of Clinical Oncology (ASCO), and is a frequent participant in international medical academic conferences. He has published many articles in Chinese scientific journals such as the Chinese Journal of Clinical Medicine Research and the Chinese Journal of Cancer Research.
For more in-depth knowledge of the mechanisms behind BRM therapeutics and to download published scientific articles regarding BRM, click here.